Long-Term Quality of Life After Ablation of Atrial Fibrillation The Impact of Recurrence, Symptom Relief, and Placebo Effect by Wokhlu, Anita et al.
A
U
q
F
T
A
M
f
t
M
S
s
n
c
t
S
U
D
a
M
g
2
Journal of the American College of Cardiology Vol. 55, No. 21, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PQUARTERLY FOCUS ISSUE: HEART RHYTHM DISORDERS
Long-Term Quality of Life
After Ablation of Atrial Fibrillation
The Impact of Recurrence, Symptom Relief, and Placebo Effect
Anita Wokhlu, MD, Kristi H. Monahan, RN, David O. Hodge, MS, Samuel J. Asirvatham, MD,
Paul A. Friedman, MD, Thomas M. Munger, MD, David J. Bradley, MD, PHD,
Christine M. Bluhm, RN, Janis M. Haroldson, RN, Douglas L. Packer, MD
Rochester, Minnesota
Objectives We sought to determine the relationship between atrial fibrillation (AF) ablation efficacy, quality of life (QoL),
and AF-specific symptoms at 2 years.
Background Although the primary goal of AF ablation is QoL improvement, this effect has yet to be demonstrated in the long term.
Methods A total of 502 symptomatic AF ablation recipients were prospectively followed for recurrence, QoL, and AF symptoms.
Results In 323 patients with 2 years of follow-up, 72% achieved AF elimination off antiarrhythmic drugs (AADs), 15%
achieved AF control with AADs, and 13% had recurrent AF. The physical component summary scores of the Medical
Outcomes Study Short Form 36 increased from 58.8  20.1 to 76.2  19.2 (p  0.001) and the mental component
summary scores of the Short Form 36 increased from 65.3  18.6 to 79.8  15.8 (p  0.001). Post-ablation QoL
improvements were noted across ablation outcomes, including recurrent AF (change in physical component summa-
ry: 12.1  19.7 and change in mental component summary: 9.7  17.9), with no significant differences in QoL im-
provement across 3 ablative efficacy outcomes. However, in 103 patients who completed additional assessment with
Mayo AF Symptom Inventories (on a scale of 0 to 48), those with AF elimination off AADs had a change in AF symp-
tom frequency score of 9.5  6.3, which was significantly higher than those with AF controlled with AADs (5.6 
3.8, p  0.03) or those with recurrent AF (3.4  8.4, p  0.02). Independent predictors of limited QoL improve-
ment included higher baseline QoL, obesity, and warfarin use at follow-up.
Conclusions AF ablation produces sustained QoL improvement at 2 years in patients with and without recurrence. AF-specific
symptom assessment more accurately reflects ablative efficacy. (J Am Coll Cardiol 2010;55:2308–16)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.040(
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jtrial fibrillation (AF) affects 6.7 million people in the
.S. and Europe (1,2). People with AF have impaired
uality of life (QoL) compared with the general population
rom the Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
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ual property rights for Bard EP, Hewlett Packard, Medical Positioning, Inc., Aegis
edical, and NeoChord; and has served as a speaker/consultant for Medtronic, Boston
cientific, and St. JudeMedical. Dr. Packer in the past 12 months has provided consulting
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Contact, Sanofi-Aventis, St. JudeMedical, and Toray Industries; he received no personal
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Manuscript received August 5, 2009; revised manuscript received November 23,
009, accepted January 2, 2010.3,4). Thus, the impetus to eliminate AF has been great.
aintenance of sinus rhythm with antiarrhythmic drugs
AADs), however, has not been shown to have consistent
uperior benefits in QoL, major physical end points, stroke,
r survival over rate-control strategies (4–6).
See page 2317
Primary curative AF ablation, with the potential for
reater efficacy and freedom from the adverse side effects of
ADs, is a viable option for select symptomatic patients
7,8). Post-ablation QoL improvement and/or a superior
oL benefit from ablation over pharmacologic rhythm
ontrol have been demonstrated in studies with limited
ample sizes and follow-up durations 1 year (9–14).
evertheless, establishing that QoL benefit lasts beyond 1
ear and is attributable to ablation-specific effects would
ustify the broader application of this expensive procedure
ith uncommon, but significant risks.
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May 25, 2010:2308–16 Quality of Life After AF AblationThe purpose of this prospective observational study was
o establish the impact of AF ablation on QoL in symp-
omatic patients and to identify the relative contributions of
atient-related factors, rhythm status, AAD use, and relief
f AF-specific symptom burden.
ethods
atient population. We included 502 consecutive patients
ith symptomatic AF who underwent AF ablation at Mayo
linic, a large tertiary care referral center. The decision to
roceed with ablation was made by an electrophysiologist,
sually after a symptomatic patient had failed to respond to
trial of at least 1 AAD or had side effects and rarely as a
rst-line AF therapy, per current consensus recommenda-
ions (7). Symptomatic patients undergoing AF ablation
ere prospectively followed for QoL and rhythm outcomes
rom December 2001 until July 2006. Data were collected
rospectively until March 2008. This study was approved by
he Mayo Institutional Review Board, and all patients
rovided informed consent.
blation protocol. Patients discontinued amiodarone for 2
onths before ablation and other AADs for 5 half-lives.
atients underwent a previously described AF ablation
rotocol (15). Patients underwent either a lasso-guided,
ircumferential pulmonary vein (PV) isolation (n  117,
2%) or an electroanatomically mapping–guided, wide area
ircumferential ablation (n  385, 78%) with additional
inear lesions along the left atrial roof and the left inferior
sthmus. During PV isolation, ablation was guided by the
asso mapping catheter positioned near the orifice of the
Vs, with localization by intracardiac echocardiography.
uring wide area circumferential ablation, electroanatomic
aps of the PVs and left atrium were rendered using
avigational mapping tools. With either approach, entrance
lock to the PVs, an acute end point of the ablation, was
onfirmed by a lasso catheter. Additional ablation targets
ncluded residual PV potentials and non-PV foci in the
etting of recurrent spontaneous or induced AF during
soproterenol infusion (5 to 15 g/min). Patients also
niformly underwent cavotricuspid isthmus ablation.
utcomes assessment. Post-procedure, patients remained
ospitalized and were monitored for 24 to 48 h. Clinical
ollow-up was recommended at 3 months and annually.
efore and after ablation at 3 months and 1, 2, and 3 years,
atients received a questionnaire that included QoL assess-
ent, symptom information, and self-reports of arrhythmia
ecurrences (and interventions) that occurred outside of
ollow-up visits. All reported outcomes were timed in
elation to the patient’s last ablation at Mayo Clinic.
Health-related QoL was assessed with the Medical Out-
omes Study Short Form-36 (SF-36). The SF-36 contains
individual scales, scored from 0 (worst health) to 100 (best
ealth). Raw scores were presented as T scores in compar-
son with a healthy normal population with a mean score set at
0 with an SD of 10. In addition to a total score, physical oomponent summary (PCS) and
ental component summary
MCS) scores were assessed on a
aw scale of 0 to 100 (14).
After August 2004, the Mayo
F-Specific Symptom Inventory
MAFSI) was introduced to clin-
cally follow AF-specific symp-
oms (16). Although it has some
ommon elements with the
ymptom Checklist (survey devel-
ped by R.S. Bubien and G.N.
ay, and revised by L.S. Jenkins,
993), the MAFSI inventory
onitors additional symptoms
Packer DL, Kay GN, Bubien RS,
ersonal communication, 2009) (17,18). Using a checklist of
2 symptoms, patients score the frequency of symptoms over 6
onths as 0 (never), 1 (rarely), 2 (sometimes), 3 (often), and 4
always). Total scores range from 0 to 48.
Recurrence was counted as any atrial arrhythmia that
ccurred after the post-procedural blanking period of 2
onths, including atrial flutter and atrial tachycardia.
lanking recurrences were noted but not counted because of
heir unclear long-term significance. Asymptomatic recur-
ences were detected at routine clinical follow-up, which
ncluded a physical examination and electrocardiogram as
ell as Holter monitoring that was obtained typically at 3
nd 12 months and then at the discretion of the patient’s
ardiologist. Symptomatic recurrences were identified at
linical follow-up and by a 3-month and then annual
uestionnaires and were confirmed electrocardiographically.
epeat ablations were generally delayed until 6 months after
he initial ablation procedure.
Between follow-ups, patients were instructed to call in
nformation regarding recurrences, cardioversions, and
omplications. Research staff or the patient’s electrophysi-
logist contacted the patient to facilitate Holter or event
onitoring to document arrhythmia when the diagnosis
as uncertain. Quarterly chart review was also performed.
AD, warfarin, or aspirin use, cardioversions, and addi-
ional AF interventions were noted.
Ablative efficacy was categorized as AF elimination off
ADs, AF control on AADs, and recurrent AF. AF elimina-
ion was achieved in patients who were arrhythmia free and off
ADs for at least 6 months before evaluation. This group
ncompassed those patients in whom complete freedom from
ost-blanking recurrence was achieved for the duration of
ollow-up off AADs (96%) as well as those who had early
ecurrences that self-resolved without the need for long-term
AD therapy (4%). AF control on AADs was achieved in
atients who maintained sinus rhythm for at least 6 months
efore assessment, but who had recurrence at some point and
equired AADs. Patients without AF control despite AAD use
Abbreviations
and Acronyms
AAD  antiarrhythmic drug
AF  atrial fibrillation
MAFSI  Mayo AF-Specific
Symptom Inventory
MCS  mental component
summary
PCS  physical component
summary
PV  pulmonary vein
QoL  quality of life
SF-36  Medical Outcomes
Study Short Form-36r repeat ablations were considered to have recurrent AF.
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Quality of Life After AF Ablation May 25, 2010:2308–16tatistical methods. Continuous data were expressed as
ean  SD. Using the chi-square test for categorical
ariables and the Kruskal-Wallis test for continuous vari-
bles, patient characteristics were compared in patients who
id and did not complete QoL follow up at 2 years and in
atients who did and did not complete a baseline MAFSI
ssessment. Changes in SF-36 or MAFSI scores from
aseline to various time points were assessed using paired t
ests. A 1-way analysis of variance was used to compare
hanges in SF-36 and MAFSI scores in patients based on a
-tiered rhythm status outcome. The Bonferroni method
as performed to adjust for multiple comparisons. Corre-
ations were ascertained using Pearson correlation coeffi-
ients. Univariate linear regression relationships between: 1)
aseline demographic characteristics; 2) baseline echocar-
iographic characteristics; 3) pharmacological therapies at 2
ears; and 4) baseline PCS and MCS scores and QoL
mprovement at 2 years were described. If the p value was
0.15 in a univariate model, then an additional t test or
nalysis of variance was performed. Two linear multivariate
egression models with stepwise selection of univariates with
 0.05 were constructed to assess independent predictors
f QoL improvement. The first model included all signifi-
ant univariates except baseline PCS and MCS scores, but
hese were incorporated into the second model. For all
tatistical tests, a 2-tailed p value 0.05 was considered
Clinical Characteristics of Patients With and WiTable 1 Clinical Characteristics of Patients
Overall Cohort
(n  502)
Demographic and echocardiographic
features
Age (yrs) 55.9 10.3
Male 410 (82)
Paroxysmal AF 256 (51)
Persistent AF 175 (35)
Long-standing AF 65 (13)
AF duration (yrs) 6.6 5.9
WACA ablation (vs. PVI) 385 (78)
LV ejection fraction (%) 58.0 9.7
LA size 45 mm 175 (35)
Underlying disease
Heart failure 11 (2)
Coronary artery disease 56 (11)
Diabetes 33 (7)
Dilated cardiomyopathy 46 (9)
Hypertension 195 (39)
Valvular heart disease 59 (12)
Sleep apnea 67 (13)
Pre-ablation medications
Any AAD therapy failed 459 (91)
Any rate control therapy failed 406 (81)
Beta-blockers 242 (68)
Calcium-channel blockers 186 (37)
Values are mean  SD or n (%).
AAD antiarrhythmic drug; AF atrial fibrillation; echo echocardiographi
WACA  wide area circumferential ablation.ignificant. Analyses were performed using SAS version 8.2
SAS Inc., Cary, North Carolina).
esults
linical characteristics. Clinical characteristics of 502
ymptomatic patients who underwent ablation are shown in
able 1. Previous AF ablations had been performed in 12%
f the cohort at Mayo Clinic and in 12% elsewhere. The
edian duration of follow-up was 3.1 years (interquartile
ange 2.1 to 4.2 years). At 24 months, QoL and ablative
fficacy data were available for 323 of 502 patients (64%).
he clinical and echocardiographic characteristics of the
atients who did and did not complete a QoL inventory at
4 months are compared in Table 1. The only significant
ifference between these groups was that patients with
onger follow-up, as expected, less frequently underwent
ide area circumferential ablation, which was incorporated
nto our practice approximately 3 years after the study began.
ealth-related QoL. Baseline total SF-36 scores before
he first ablation (63.9  19.2) and last ablation (64.1 
8.7) were similar. Compared with baseline scores before
he last ablation, total mean SF-36 scores increased signif-
cantly to 80.8  15.6 at 3 months after the last ablation
p  0.001). This improvement was sustained at 12 months
80.6  15.7, p  0.001) and 24 months (80.5  16.5, p 
.001). The early and sustained QoL improvement was
2-Year Follow-Upand Without 2-Year Follow-Up
ears of Follow-Up
(n  179)
>2 Years of Follow-Up
(n  323) p Value
54.9 10.5 56.4 10.2 0.09
144 (80) 266 (82) 0.60
97 (54) 149 (46) 0.08
64 (36) 109 (34) 0.64
26 (15) 39 (12) 0.43
6.7 5.7 6.6 6.0 0.89
153 (85) 232 (72) 0.001
57.7 8.9 58.1 10.1 0.12
68 (38) 107 (33) 0.27
6 (3) 5 (2) 0.19
20 (11) 36 (11) 0.99
16 (9) 17 (5) 0.11
18 (10) 28 (9) 0.61
62 (35) 133 (41) 0.15
22 (12) 37 (11) 0.79
24 (13) 43 (13) 0.96
158 (88) 301 (93) 0.06
146 (82) 260 (81) 0.77
120 (68) 219 (68) 0.96
71 (40) 115 (36) 0.30thoutWith
<2 Yc; LA left atrial; LV left ventricular; PVI pulmonary vein isolation;
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May 25, 2010:2308–16 Quality of Life After AF Ablationimilar for both physical and mental health, as Figure 1
llustrates. From baseline to 24 months, the mean PCS
core of 58.8  20.1 increased to 76.2  19.2 (p  0.001)
nd the mean MCS score increased from 65.3  18.6 to
9.8  15.8 (p  0.001) All 8 scales of the SF-36 with the
xception of body pain contributed significantly to overall
oL improvement, as shown in Figure 2. For reference,
ach scale was calibrated to population-based norms where
n adjusted score of 50  10 represents the mean  SD
cores of the entire U.S. population in any of the 8
ategories. The areas of improvement ranked in order from
reatest to least were physical role, vitality, social function,
hysical function, general health, emotional role, mental
ealth, and body pain, resulting in a return to the norm for
ll domains.
Figure 1 Physical and Mental Health Over 24 Months After Abl
Quality of life measured by the Medical Outcomes Study Short Form 36 physical c
is shown at baseline and 3, 12, and 24 months after ablation. *p  0.001 comp
Figure 2 Norm-Based Improvements on
SF-36 Scales Over 24 Months
Eight subscales of the Medical Outcomes Study Short Form 36 (SF-36) normal-
ized to a healthy normal population (50  10) are shown at baseline and 24
months after ablation. *p  0.001 compared with baseline with Bonferroni
adjustment. Gen  general; Phys  physical.pnfluence of ablative efficacy. Of the 323 patients, 224
69%) were completely free of post-blanking recurrence and
9 (31%) had at least 1 post-blanking recurrence at 2 years.
n the recurrence-free group, improvements in QoL scores
PCS: 16.6  17.4, MCS: 13.1  16.6) were higher
han in those who had a recurrence (PCS: 13.7  18.9,
MCS: 11.8  19.8), but these differences were not
ignificant (p  0.131 and p  0.681, respectively).
At 2 years, 66 patients (20%) remained on either amio-
arone (4%) or another AAD (16%) and 150 patients (46%)
emained on beta-blockers (36%) or calcium-channel block-
rs (14%) for a variety of indications. Among 323 patients,
33 (72%) achieved AF elimination off AADs, 48 (15%)
chieved AF control on AADs, and 42 had recurrent AF
13%) at 24 months. Among the 42 patients with recurrent
F, 5 patients underwent atrioventricular nodal ablation
ith pacemaker placement or the surgical Maze procedure
12%), 18 required AADs (43%), and 27 (64%) remained
oncurrently on some form of rate-control agent. As Figure 3
llustrates, post-ablation improvements in QoL were substan-
ial across all ablation outcomes, including those with recurrent
F (PCS: 12.1  19.7 and MCS: 9.7  17.9). No
ignificant differences in QoL improvement were noted among
blation efficacy outcomes.
nfluence of repeat ablation. Fifty-nine patients in the
ohort had multiple AF ablations and completed QoL
ssessments for both the first and repeat ablations. Although
aseline QoL scores in this subgroup improved from 64.7
1.8 before the first ablation to 72.5 18.7 (p 0.04) after
months, scores then decreased to 64.3  17.1 before
epeat ablation (p  0.77), when the mean time to repeat
blation was 2.0 1.6 years. At 2 years after repeat ablation,
he QoL score improved to 77.3  16.3 (p  0.03
ompared with baseline). This was comparable to improve-
ents seen in the cohort overall.
nfluence of long-term anticoagulation. From the stand-
ent summary (PCS) and mental component summary (MCS) scores
ith baseline with Bonferroni adjustment.ation
ompon
ared woint of anticoagulation, 320 (64%) patients in the initial
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Quality of Life After AF Ablation May 25, 2010:2308–16ohort reported warfarin use before ablation, and all patients
ere discharged on warfarin (with heparin bridging until
herapeutic) for at least 3 months. Among the 306 patients
ith efficacy data, warfarin was continued in 96 patients
31%) and discontinued in 210 patients (69%) after a time to
iscontinuation of 1.1  0.8 years. Patients maintained on
arfarin had higher median CHADS2 (Congestive Heart
ailure, Hypertension, Age 75 years, Diabetes, Secondary
revention of Stroke or Transient Ischemia Attack [2])
cores (1, interquartile range 0 to 1) than their counterparts
ff warfarin (0, interquartile range 0 to 1, p  0.003) and
ere more likely to have persistent AF, severe left atrial
nlargement, sleep apnea, or a history of stroke. Seven of the
patients who had stroke or transient ischemic attacks
xperienced them within the first 3 months, necessitating
ong-term anticoagulation, whereas 1 patient had a stroke 3
ears after discontinuation of anticoagulation. The median
HADS2 score of this group was 1 (range 0 to 2), including
patient who had a mechanical mitral valve prosthesis. At
years, those who remained on warfarin had less SF-36
mprovement than those who did not (9.9  16.5 vs.
16.3  16.8, p  0.008).
F symptom frequency score to assess the impact of
blation. Of the original 502 patients, 226 who enrolled
rom August 2004 to June 2006 (45% of the cohort)
ompleted baseline MAFSI surveys. Compared with the
ubgroup who did not complete baseline MAFSI surveys,
he subgroup who did had a less paroxysmal AF (46% vs.
5%, p 0.04), more left atrial enlargement45 mm (40%
s. 30%, p  0.02), and more hypertension (44% vs. 35%,
 0.04). Both baseline and 24-month MAFSI surveys
ere completed in 106 patients (21%), of whom 103 had
ocumented rhythm status at 24-month (20%) follow-up.
Mean AF symptom frequency scores before the first
blation (14.3 6.5) and the last ablation (14.1 6.4) were
Figure 3 Quality of Life Based on Post-Ablation Rhythm Status
Improvements in PCS and MCS scores are compared in patients with atrial fibrillat
AF control on antiarrhythmic drugs (AAD), and patients without AF control, or recurimilar. Symptom frequency scores decreased from 14.1 .4 to 4.8  5.3 (p  0.001). Statistically significant
mprovements were observed in all individual symptom
ategories except ankle swelling and unexplained falls.
arked individual symptom improvements (by at least 1 of
grades) were observed with palpitations (2.4  1.0 to
.0  0.9, p  0.001), tiredness (2.2  1.0 to 1.0  1.1,
 0.001), and inability to exercise (1.5 1.2 to 0.5 0.9,
 0.001) (Fig. 4)
AF symptom frequency scores correlated strongly with
otal SF-36 scores in the 226 patients who completed
aseline symptom surveys (r  0.64, p  0.001) and in
he 204 patients who completed 24-month symptom sur-
F) elimination,
. Abbreviations as in Figure 1.
Figure 4 Change in Atrial Fibrillation-Specific
Symptoms (0 to 4 Scale) Over 24 Months
The Mayo Atrial Fibrillation-Specific Symptom Inventory is a checklist of 12
symptoms: palpitations (Palps), tiredness or fatigue, shortness of breath
(SOB), dizziness (Dizzy), exertional intolerance (Exert), flushing (Flush), weak-
ness (Weak), a sense of low heart rate (HR), swelling (Swell), chest pain
(ChPain), fainting or near fainting (Faint), and falls.ion (A
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May 25, 2010:2308–16 Quality of Life After AF Ablationeys (r  0.73, p  0.001) (Fig. 5). In 103 patients for
hom complete symptom, QoL, and recurrence status
ollow-up at 24 months and baseline was available, improve-
ents in AF symptoms and QoL correlated moderately
r  0.55, p  0.001).
Unlike changes in QoL, changes in AF symptoms dif-
ered significantly among ablation efficacy outcomes
Fig. 6). In 103 patients, 75 with AF elimination off AADs
ad a change in the AF symptom frequency score of 9.5
6.3, which was nearly significantly higher than the change
n AF symptom frequency score in the 18 patients with AF
ontrol on AADs (5.6  3.8, p  0.06) and significantly
Figure 5 Correlation of Frequency of AF Specific Symptoms Wi
The correlation Medical Outcomes Study Short Form 36 (SF-36) scores and Mayo
at pre-ablation (left) and after ablation (right). Higher quality of life (QoL) scores a
Figure 6 Change in AF Symptom Score
Based on Post-Ablation Rhythm Status
One-way analysis of variance comparison of symptom
improvements with mean  SD are shown. Abbreviations as in Figures 3 and 5.pigher in the 10 patients with recurrent AF (3.4  8.4, p
0.04).
redictors of QoL benefit. Three univariate predictors
p  0.05) of an improvement in total QoL score at 24
onths after ablation were identified: obesity defined as
ody mass index 30 kg/m2 (p  0.04), warfarin at
ollow-up (p  0.003), and baseline SF-36 score (p 
.0001). In the subgroup of patients who completed base-
ine MAFSI surveys, high baseline symptom scores were
lso identified as a predictor of QoL outcomes. Table 2
emonstrates the differences in QoL improvement for select
atient characteristics including all significant factors.
In a multivariate analysis (which did not include baseline
ymptom score), warfarin use at follow-up predicts a 10-
oint decrease in SF-36 score improvement (SE  2.0, p 
.0001). Obesity (body mass index 30 kg/m2) predicts a
.8-point decrease in SF-36 score improvement (SE  1.8,
 0.0002). Higher baseline SF-36 scores also predict less
obust QoL improvement. Each 10-point increase in base-
ine SF-36 is associated with a 3-point decrease in QoL
mprovement (SE  0.7, p  0.0001), with differences in
aseline MCS and PCS scores having equivalent effects on
oL improvement.
mpact of complications. Major procedural complications
nd long-term follow-up events with potential for QoL
mpact were experienced by 43 patients (10 with cardiac
amponade requiring pericardiocentesis, 4 with in-hospital
ransient ischemic attack or stroke, 4 with transient ischemic
ttack or stroke sometime during follow-up, 1 with intra-
erebral hemorrhage, 24 with computed tomography evi-
ence of pulmonary vein stenosis of whom 4 required
ntervention for symptoms, and none with gastroesophageal
njury or fistula). QoL data were available for 30 of 43
L
cific Symptom Inventory (MAFSI) scores is shown
er symptom scores correspond to clinical improvement.th Qo
AF-Spe
nd lowatients with complications. In a univariate analysis, the
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Quality of Life After AF Ablation May 25, 2010:2308–16resence of post-procedural complications including stroke
id not have a long-term impact on QoL improvement. In
ddition, the decreased QoL improvement in obese patients
nd those on warfarin at follow-up was not significantly
ssociated with an increased rate of any complication or
troke.
iscussion
n this prospective study of AF ablation recipients, a marked
nd sustained improvement in QoL at 2 years occurred in
ost patients. Although QoL seemed to improve with
epeat ablations, QoL improvement was not closely linked
o overall ablative efficacy. Despite a trend toward greater
hysical QoL improvement in patients with AF elimina-
ion, substantial QoL improvement was also seen in patients
ith AF control on AADs and those with recurrent AF.
eterminants of limited QoL improvement included obe-
ity, ongoing warfarin use, and a good baseline QoL. In
nivariate Relationships of QoL ImprovementTable 2 Univariate Relationships of QoL Improvement
Characteristic QoL Change p Value
AF
Paroxysmal 13.4 15.0
0.31
Nonparoxysmal 15.5 18.8
LA size, mm
45 14.0 16.1
0.90
45 14.6 17.4
Post-procedural complication 17.2 17.4
0.16
No post-procedural complication 14.0 16.8
Hypertension 12.6 16.6
0.06
No hypertension 15.7 17.1
Obese 11.9 18.5
0.05
Nonobese 16.4 16.2
AF elimination off AAD 14.9 16.8
0.62AF controlled on AAD 13.9 16.4
Recurrent AF 11.8 17.7
On warfarin at 2 yrs 9.9 16.5
0.008
Off warfarin at 2 yrs 16.3 16.8
On beta-blocker at 2 yrs 13.2 17.6
0.33
Off beta-blocker at 2 yrs 14.8 16.4
On calcium-channel blocker at 2 yrs 10.8 13.8
0.16
Off calcium-channel blocker at 2 yrs 12.2 17.2
Repeat AF ablations 10.5 16.3
0.83
Single AF ablation 12.2 17.0
Baseline SF-36, %
0–25 26.8 20.2
0.001
26–50 17.9 16.3
51–75 10.7 12.2
76–100 3.0 6.5
Baseline MAFSI, %
0–25 8.1 16.0
0.01
26–50 16.5 15.1
51–75 14.6 15.2
76–100 22.0 16.8
AFSI  Mayo AF-Specific Symptom Inventory; SF-36  Medical Outcomes Study Short Form 36;
ther abbreviations as in Table 1.ontrast to the nonspecific relationship between QoL im- crovement by SF-36 scores and AF ablation efficacy,
hanges in AF-specific symptoms by MAFSI scores more
onsistently reflected ablative efficacy.
ong-term QoL benefit. The clinical relevance of these
ndings is substantial. According to the consensus report on
F ablation from the Heart Rhythm Society, “the primary
ustification for an AF ablation procedure. . .is the presence
f symptomatic AF, with a goal of improving a patient’s
uality of life” (7). In most of our cohort, there was not only
mprovement, but also normalization of QoL seen as early
s 3 months. The finding of a durable 2-year QoL benefit
xtends previous findings of a 1-year or less benefit (7,9–14).
herefore, the longevity of the QoL improvement after abla-
ion potentially strengthens the argument for ablation in
atients with symptomatic AF.
However, the lack of a strong relationship between the
egree of QoL improvement and ablation efficacy raises
uestions about the specificity of the QoL effect of ablation
nd its mode of assessment. In this cohort, we found little
ifference in QoL improvement between the 69% of pa-
ients who were entirely free of recurrence at 2 years off
ADs and the remaining 31% who experienced recur-
ences. Recognizing that freedom from sustained symptom-
tic recurrences due to rhythm control could be as favorably
erceived by patients as absolute freedom from any recur-
ence, we also assessed QoL based on rhythm control off
nd on AAD. Although patients with AF elimination had
substantial QoL improvement, so too did those with AF
ontrol on AADs and those with limited recurrent AF.
oL improvement in recurrent AF. The QoL improve-
ent observed in patients with recurrent AF may be
ttributable to a variety of causes. In some cases, QoL
mprovement may have been due to other efficacious AF
nterventions including atrioventricular node ablation or the
urgical Maze procedure. Alternatively, those with recurrent
F may represent a less symptomatic group post-ablation
han those who sought those interventions or repeat abla-
ion. Such transition to less severe or asymptomatic disease
tates could be due to direct ablation effects, secondary
estruction of autonomic inputs to the atrium, or improved
harmacologic efficacy (19). Nonetheless, only minor im-
rovements in AF-specific symptom burden were observed
n patients with recurrent AF despite substantive QoL
mprovements. Therefore, regression to the mean, placebo
ffect, and the limitations of SF-36 as a metric of ablation
fficacy need to be considered.
The principle of regression to the mean is that patients
ay be less symptomatic on average than they report at
resentation, thus predisposing to an overestimation of
ymptom or QoL improvement. This effect seems unlikely
ecause patients frequently wait for months from the time
f ablation referral to the actual time of procedure and
aseline questionnaire completion. Placebo effect is another
otential explanation for the lack of correlation between
reatment effect and QoL outcomes in this study. The actual
ontribution of placebo effect is hard to define given the
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May 25, 2010:2308–16 Quality of Life After AF Ablationthical problems with sham invasive procedures (7). Al-
hough the consistent nature of QoL improvement at 3, 12,
nd 24 months does not favor a placebo effect, there are
xamples of placebo effect lasting beyond 1 year (20,21).
lternatively, our findings suggest that the SF-36 does not
ntirely describe the QoL burden that a sporadic disease
rocess such as AF imposes on a person’s well-being.
ontributors to symptom improvement. Other factors
bscured the relationship between rhythm status and QoL,
ncluding obesity and ongoing warfarin therapy. Procedural
omplications (including stroke) were not significantly
igher in either subgroup, nor were overall complications of
ufficient frequency or magnitude to diminish the QoL
mprovement in these entire subgroups. In obese patients,
imited QoL improvement may reflect diminished underly-
ng functional capacity. In some patients requiring warfarin,
he inconvenience of international normalized ratio moni-
oring or nuisance bleeding may explain limitations in QoL
mprovement.
arfarin and QoL. The impact of warfarin on QoL raises
uestions regarding the unaccepted ablation indication for
iscontinuation of anticoagulation. Although one random-
zed study of anticoagulation in patients with AF demon-
trated no detrimental impact of warfarin use on QoL, our
tudy suggests that in post-ablation patients, the QoL
enefit of ablation is decreased in patients on long-term
nticoagulation therapy (22). This may relate to patient
erceptions of less stroke risk after AF elimination and,
herefore, less benefit of anticoagulation or that sicker
atients with less potential for QoL improvement were
nticoagulated in the long term. Although limited data
uggest that the judicious discontinuation of long-term
nticoagulation therapy after AF ablation, applied on an
ndividualized basis, does not increase stroke risk, additional
tudy is required (23). Nonetheless, anticoagulation during
nd early after the procedure remains critically important,
iven that transient ischemic attacks or strokes in this study
ccurred predominantly within 3 months of the procedure.
F-specific symptom scoring. Elimination of AF-specific
ymptoms may be a better end point for ablative therapy
han generic QoL. We found that the use of AF-specific
ymptom assessment with MAFSI, a simple survey, pro-
ided clinically relevant, disease-specific information that
ore directly reflected rhythm status and clinical improve-
ent at 2 years. Specifically, palpitations, tiredness, short-
ess of breath, dizziness, and perceived limitations in
xertional capacity should be assessed because these are the
ost problematic at baseline and improve the most after
blation.
tudy limitations. The main limitation is that the data are
erived from a prospective cohort rather than from a
andomized, controlled cohort comparing AF ablation ther-
py to best pharmacological therapy. In addition, it is
mportant to note that the ablation practices described here
o not incorporate the targeting of complex fractionated
lectrograms, which may augment ablative efficacy. Anotherimitation of this study is that the mode of detecting
ecurrence was largely clinically driven. The use of either
mplantable atrial monitoring or frequent screening with
uto-detection full disclosure monitors may better identify
he frequency of asymptomatic recurrences and their impact
n QoL.
onclusions
his study compares ablation efficacy status, QoL, and
F-symptom score assessments. We found the QoL im-
rovement after ablation was not entirely dependent on
blative efficacy. Other factors, including symptom relief,
aseline QoL status, baseline characteristics, and the poten-
ial for warfarin discontinuation must be considered. Atrial
brillation symptom assessments provide more disease-
pecific information than QoL tools in baseline assessment
nd clinical follow-up of patients undergoing AF ablation.
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